SIFI COMPLETES ENROLLMENT OF THE PHASE III STUDY OF POLIHEXANIDE 0.08% FOR THE TREATMENT OF ACANTHAMOEBA KERATITIS
19 Novembre 2020
The study topline results expected in the second half of 2021.
CATANIA, Italy, Nov. 19, 2020 -- SIFI, a leading ophthalmic company, announced today that it has achieved the full enrollment of 135 patients with Acanthamoeba keratitis (AK) in its pi...
> leggi